This year, breast cancer will claim the lives of nearly 40,000 women in
Under the terms of the agreement,
About Hormone Receptor-Positive Breast Cancer and SERDs Up to sixty percent of breast cancers depend on the hormone estrogen and the estrogen receptor to grow and spread. This type of breast cancer is called hormone receptor-positive breast cancer. It is typically treated with medicines, such as tamoxifen and aromatase inhibitors, that are designed to block the action at the estrogen receptor or interfere with the body s production of estrogen. Many women who receive these current hormonal agents will eventually see their disease return or worsen.
Scientists at Seragon have developed next-generation selective estrogen receptor degraders (SERDs). This class of medicines is designed to both block estradiol action at the estrogen receptor and also eliminate the estrogen receptor from the cell altogether. It is believed that SERDs change the shape of the estrogen receptor in a manner that targets it for elimination by the cell. These next-generation dual-acting SERDs may offer an improved approach to treating hormone receptor-positive breast cancer, and potentially other cancers driven by the estrogen receptor.
Seragon s lead product candidate, ARN-810, is a next-generation SERD that is currently in Phase I clinical trials for patients who have hormone receptor-positive breast cancer and have failed current hormonal agents.
Most Popular Stories
- Americans Still Pessimistic Despite Economic Growth
- Illinois Issues Fracking Rules
- Detroit Muslim Conference Stirs Controversy
- Startups Offer Smartphone Banking Apps
- 'Longmire' Cancelled, Looks for New Network
- Hip-Hop Takes Up Ferguson Cause
- Clippers Deal Started With 2 Numbers
- Echeveste Steps Down, Perez Steps Up at VPE
- Immigration Delay Throws Both Parties a Curve
- Canada, Russia Go to War (on Twitter)